Compare Amylx Pharmaceuticals Inc (AMLX) vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $41.19. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMLX | QDTY | |
|---|---|---|
Market Cap | $1.98B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $18.70 | $46.71 |
52-Week Low | $7.64 | $36.57 |
Enterprise Value | $1.70B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
QDTY trades at $41.18, up 0.33% with a bearish technical outlook from moving averages. The stock shows consistent weekly dividend distributions but lacks available fundamental data for valuation or profitability metrics. Recent news highlights ongoing dividend announcements from YieldMax ETFs, indicating a focus on income generation.
The outlook is cautious due to weak technical signals and missing financials. Investment appeal hinges on dividend consistency, but risks include lack of earnings visibility and bearish momentum. Investors require updated SEC filings to assess fundamental health amid current technical pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →
